Position of the Transparency Council – Tremfya (guselkumab)
At its meeting on 1 August 2022 the Transparency Council adopted Position No. 70/2022 on the evaluation of the drug Tremfya (guselkumab) under the drug programme: “Treatment of active psoriatic arthritis (ICD-10 L40.5, M07.1, M07.2, M07.3)”.